Poxel
Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases. Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, with a focus on non-alcoholic steatohepatitis (NASH) an
Basic Information
- Category: Rare Diseases
- Founded: 2021
- Headquarters: Lyon, France
- Website: poxelpharma.com
Evidence and Sources
- Poxel — Official Site (official)
Citation Guidance
Explore Rare Diseases profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Poxel.
- Canonical profile: https://brandsource.ai/brands/poxel
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/poxel/json-ld
- Citation profile API: https://brandsource.ai/api/brands/poxel/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (74/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:04.143Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases. Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, with a focus on non-alcoholic steatohepatitis (NASH) an
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.